日本語
 
Help Privacy Policy ポリシー/免責事項
  詳細検索ブラウズ

アイテム詳細


公開

Preprint

The nuclear speckles protein SRRM2 is a new therapeutic target molecule on the surface of cancer cells

MPS-Authors
/persons/resource/persons198889

Ilik,  Ibrahim       
Quantitative RNA Biology (Tugce Aktas), Independent Junior Research Groups (OWL), Max Planck Institute for Molecular Genetics, Max Planck Society;

/persons/resource/persons231875

Aktas,  Tugce       
Quantitative RNA Biology (Tugce Aktas), Independent Junior Research Groups (OWL), Max Planck Institute for Molecular Genetics, Max Planck Society;

External Resource
There are no locators available
Fulltext (restricted access)
There are currently no full texts shared for your IP range.
フルテキスト (公開)

2024.04.26.591288v1.full.pdf
(プレプリント), 5MB

付随資料 (公開)
There is no public supplementary material available
引用

Kellner, M., Hörmann, J., Fackler, S., Yuanyu, H., Tielin, Z., Lin, L., Ilik, I., Aktas, T., Feederle, R., Hauck, S. M., Gires, O., Gärtner, K., Lietao, L., & Zeidler, R. (2024). The nuclear speckles protein SRRM2 is a new therapeutic target molecule on the surface of cancer cells. bioRxiv. doi:10.1101/2024.04.26.591288.


引用: https://hdl.handle.net/21.11116/0000-000F-5F24-F
要旨
The membrane composition of extracellular vesicles (EVs) largely reflects that of the plasma membrane of the cell of origin. We therefore hypothesized that EVs are a source for the detection of hitherto unknown tumor-associated druggable target molecules. For this, we used EVs derived from cancer cell lines for an immunization of a rat. From this immunization, we obtained a monoclonal antibody specific for SRRM2, a protein involved in splicing a major component of nuclear speckles. Here, we used this antibody to demonstrate that SRRM2 is exposed at the surface of most cancer cell lines from various entities and, even more important, on cancer cells in vivo. Moreover, we demonstrate that SRRM2-specific CAR-T cells are killing SRRM2-positive cancer cells electively. Collectively, we identified SRRM2 as a promising new target molecule exposed on the cancer cell surface and show that our SRRM2-specific antibody can be used as a basis for the development of new targeted cancer therapies.